A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

NCT05346952 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG: TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.